These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 24944075)
21. SSRIs vs. SNRIs for Vasomotor Symptoms of Menopause. Newhouser LM; Maneval M; Rayalam K; Sabeeh G; Varela L Am Fam Physician; 2022 Apr; 105(4):430-431. PubMed ID: 35426647 [No Abstract] [Full Text] [Related]
22. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. Stearns V; Beebe KL; Iyengar M; Dube E JAMA; 2003 Jun; 289(21):2827-34. PubMed ID: 12783913 [TBL] [Abstract][Full Text] [Related]
23. The effect of serotonin reuptake inhibitors on the vaginal epithelium in postmenopausal women. Shea AK; Meschino D; Wolfman W Climacteric; 2019 Oct; 22(5):507-510. PubMed ID: 31060386 [No Abstract] [Full Text] [Related]
24. Efficacy of desvenlafaxine succinate for menopausal hot flashes. Tella SH; Gallagher JC Expert Opin Pharmacother; 2014 Nov; 15(16):2407-18. PubMed ID: 25252697 [TBL] [Abstract][Full Text] [Related]
25. Management of Menopausal Symptoms: A Review. Crandall CJ; Mehta JM; Manson JE JAMA; 2023 Feb; 329(5):405-420. PubMed ID: 36749328 [TBL] [Abstract][Full Text] [Related]
26. Treating functional impairment of autism with selective serotonin-reuptake inhibitors. Moore ML; Eichner SF; Jones JR Ann Pharmacother; 2004 Sep; 38(9):1515-9. PubMed ID: 15292500 [TBL] [Abstract][Full Text] [Related]
27. Assessing risks and benefits of nonhormonal treatments for vasomotor symptoms in perimenopausal and postmenopausal women. Thacker HL J Womens Health (Larchmt); 2011 Jul; 20(7):1007-16. PubMed ID: 21675874 [TBL] [Abstract][Full Text] [Related]
28. Relapse of vasomotor symptoms after discontinuation of the selective serotonin reuptake inhibitor escitalopram: results from the menopause strategies: finding lasting answers for symptoms and health research network. Joffe H; Guthrie KA; Larson J; Cohen LS; Carpenter JS; Lacroix AZ; Freeman EW Menopause; 2013 Mar; 20(3):261-8. PubMed ID: 23435022 [TBL] [Abstract][Full Text] [Related]
29. Serotonergic agents as an alternative to hormonal therapy for the treatment of menopausal vasomotor symptoms. Stearns V Treat Endocrinol; 2006; 5(2):83-7. PubMed ID: 16542048 [TBL] [Abstract][Full Text] [Related]
30. Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions. Johns C; Seav SM; Dominick SA; Gorman JR; Li H; Natarajan L; Mao JJ; Irene Su H Breast Cancer Res Treat; 2016 Apr; 156(3):415-426. PubMed ID: 27015968 [TBL] [Abstract][Full Text] [Related]
31. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Suvanto-Luukkonen E; Koivunen R; Sundström H; Bloigu R; Karjalainen E; Häivä-Mällinen L; Tapanainen JS Menopause; 2005; 12(1):18-26. PubMed ID: 15668596 [TBL] [Abstract][Full Text] [Related]
32. Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. LaCroix AZ; Freeman EW; Larson J; Carpenter JS; Joffe H; Reed SD; Newton KM; Seguin RA; Sternfeld B; Cohen L; Ensrud KE Maturitas; 2012 Dec; 73(4):361-8. PubMed ID: 23031421 [TBL] [Abstract][Full Text] [Related]
33. A review of paroxetine for the treatment of vasomotor symptoms. Slaton RM; Champion MN; Palmore KB J Pharm Pract; 2015 Jun; 28(3):266-74. PubMed ID: 25107421 [TBL] [Abstract][Full Text] [Related]
34. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Stearns V; Isaacs C; Rowland J; Crawford J; Ellis MJ; Kramer R; Lawrence W; Hanfelt JJ; Hayes DF Ann Oncol; 2000 Jan; 11(1):17-22. PubMed ID: 10690382 [TBL] [Abstract][Full Text] [Related]
35. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. Sarri G; Pedder H; Dias S; Guo Y; Lumsden MA BJOG; 2017 Sep; 124(10):1514-1523. PubMed ID: 28276200 [TBL] [Abstract][Full Text] [Related]
36. Risk of stress cardiomyopathy associated with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors: a real-world pharmacovigilance analysis. Tan B; Chen L; Yan S; Pan H; Zhang J; Wei H Sci Rep; 2024 Jul; 14(1):15167. PubMed ID: 38956425 [TBL] [Abstract][Full Text] [Related]
37. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Cipriani A; Zhou X; Del Giovane C; Hetrick SE; Qin B; Whittington C; Coghill D; Zhang Y; Hazell P; Leucht S; Cuijpers P; Pu J; Cohen D; Ravindran AV; Liu Y; Michael KD; Yang L; Liu L; Xie P Lancet; 2016 Aug; 388(10047):881-90. PubMed ID: 27289172 [TBL] [Abstract][Full Text] [Related]
38. Venlafaxine and desvenlafaxine in the management of menopausal hot flashes. Johnson ED; Carroll DG Pharm Pract (Granada); 2011 Jul; 9(3):117-21. PubMed ID: 24367464 [TBL] [Abstract][Full Text] [Related]
39. Hormone Therapy and Other Treatments for Symptoms of Menopause. Hill DA; Crider M; Hill SR Am Fam Physician; 2016 Dec; 94(11):884-889. PubMed ID: 27929271 [TBL] [Abstract][Full Text] [Related]
40. Analysis of treatment patterns and persistence on branded and generic medications in major depressive disorder using retrospective claims data. Solem CT; Shelbaya A; Wan Y; Deshpande CG; Alvir J; Pappadopulos E Neuropsychiatr Dis Treat; 2016; 12():2755-2764. PubMed ID: 27822048 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]